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Cancer patients may experience skin problems while undergoing chemotherapy and radiation therapy. Frequency of skin reactions
may be influenced by skin pigmentation and psychological factors. A Symptom Inventory completed by 656 cancer patients
nationwide before and after chemotherapy, radiation therapy, or chemotherapy plus radiation therapy was analysed to determine if
treatment type, race (Black vs White), and pretreatment expectations influenced post-treatment skin reactions. Subsequent analysis
of a local Symptom Inventory completed weekly for 5 weeks by 308 patients receiving radiation therapy examined severity of
reported skin reactions. Significantly more patients receiving radiation therapy had stronger expectations of skin problems (62%) than
patients receiving chemotherapy (40%, P¼0.001) or chemotherapy plus radiation therapy (45%, P¼0.003). Overall, expectations
did not correlate with patient reported post-treatment skin problems in white (r¼0.014, P¼0.781) or black (r¼0.021, P¼0.936)
patients. Although no significant difference was found between black and white patients in their pretreatment expectations of skin
problems (P¼0.32), black patients (10 out of 18, 56%) reported more skin problems than white patients (90 out of 393, 23%,
P¼0.001). Similarly, the local study showed that significantly more black patients (1 out of 5, 20%) reported severe skin reactions at
the treatment site than white patients (12 out of 161, 8%). A direct correlation was observed between severity of skin problems and
pain at the treatment site (r¼0.541, Po0.001). Total radiation exposure did not significantly correlate with the report of skin
problems at the treatment site for white or black patients. Overall, black patients reported more severe post-treatment skin
problems than white patients. Our results suggest that symptom management for post-treatment skin reactions in cancer patients
receiving radiation treatment could differ depending on their racial background.
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Dermatitis and other skin ailments affect 30–40% of individuals in
the general population (Freak, 2004). In the US and European
populations, approximately 2% of individuals suffer from psoriasis
(Freak, 2004; Gelfand et al, 2005). Skin problems are among the
most common side effects of cancer treatment reported by
patients, especially those undergoing radiation therapy for breast
cancer and head and neck cancer. The combination of chemo-
therapy and radiation therapy has previously been reported to cause
the worst skin reactions because chemotherapeutic drugs can
induce radiosensitivity (Alley et al, 2002). The role that treatment
regimen, skin pigmentation, and psychological factors play in the
frequency of skin reactions experienced by cancer patients remains
unclear. Possible prognostic factors for cancer treatment-related
skin reactions should be identifiable by investigating the skin
problems reported by cancer patients of different races in relation
to their treatment type and pretreatment expectations.
Skin pigmentation depends on the amount and distribution of a
ubiquitous pigment known as melanin (Nielsen et al, 2006). The
skin of darkly pigmented individuals contains larger amounts of
melanin, present as granules in melanocytes, resulting in a darker
skin tone. Melanin protects human skin from ultraviolet (UV) and
ionising radiation damage through its capacity to absorb light over
a broad spectrum (Nielsen et al, 2006). Despite the protective
capacity of melanin, both UV and ionising radiation can cause
irreparable skin damage. Consequently, cancer patients have more
severe radiation-induced skin reactions in sun-exposed areas of
the skin, suggesting additive damage (Johansson et al, 2002).
Psychological factors may also contribute to the toxicity
experienced by cancer patients undergoing treatment. The range
and severity of treatment side effects among cancer patients is
inadequately explained by pharmacological data (Koo and
Lebwohl, 2001). Schreier and Williams (2004) demonstrated that
high anxiety at the start of treatment was associated with decreased
quality of life in women undergoing radiation therapy or
chemotherapy for breast cancer. Current data suggest that further
research is required to completely understand the impact that
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spsychological factors, such as expectations, have on the cancer
treatment process. The focus of this study is to examine the
influence of expectations, race, and treatment type on post-
treatment skin reactions reported by cancer patients.
This correlative study of two Symptom Inventories completed
by cancer patients nationwide (n¼656) and locally (n¼308)
begins to establish the relationship between race (Black vs White),
treatment regimen (chemotherapy and/or radiation therapy), and/
or pretreatment expectations with post-treatment skin reaction as
reported by cancer patients. We hypothesised that black patients
would have less frequent and less severe skin problems because the
high melanin content of their skin would shield skin from
superficial damage. Cancer treatment with radiation therapy
requires repeated exposures to low-dose ionising radiation for 6
weeks, on average. Skin pigmentation is highly influenced by
radiation therapy, even when small amounts of melanin (i.e.,
pigmentation) are present.
MATERIALS AND METHODS
Nationwide Symptom Inventory
The nationwide Symptom Inventory, a single-page questionnaire,
was adapted from a similar measure created at MD Anderson
Cancer Center (Edwards et al, 2001b; Riley et al, 2002). The
Symptom Inventory has been used by our group in several studies
involving patients with cancer. The nationwide Symptom Inven-
tory consisted of a series of visual analog scales assessing the
severity of 12 symptoms (pain, fatigue, nausea, sleep problems,
feelings of depression, shortness of breath, difficulty remembering
things, weight loss, hair loss, difficulty concentrating, hot flashes
and skin problems). Patients are asked to indicate the severity of
each symptom at its worst ‘in the past week’ by filling in the
appropriate circle on an 11-point horizontal scale anchored by
0¼‘not present’ and 10¼‘as bad as you can imagine.’ The
presence of a symptom was defined as a score of at least ‘1’ on the
11-point Symptom Inventory scale. The present study focused on
the presence and severity of skin problems in relation to the
treatment regimen and race.
This report analysed 656 cancer patients who participated in the
nationwide Symptom Inventory study conducted at 31 private
community practice sites. All of the patients were approached and
asked to complete a Symptom Inventory by a clinical research
associate. Completion of the questionnaire was voluntary and took
approximately 5min. The cancer patients completed the Symptom
Inventory before and after receiving chemotherapy, radiation
therapy, or both types of treatment. The completed Symptom
Inventories became part of the patient’s clinical chart, and the
forms could be reviewed by clinical staff during regularly
scheduled patient follow-up visits. All patients included in this
study signed a patient authorisation form allowing the information
obtained from the Symptom Inventory to be stored in a Symptom
Inventory database that is maintained by the James P Wilmot
Cancer Center Behavioral Medicine Unit for research purposes.
Permission to maintain the database and for patient chart review
has been obtained from the University of Rochester Research
Subjects Review Board in accordance with HIPAA policies.
Local Symptom Inventory
The local Symptom Inventory, a single-page questionnaire, was
also adapted from a similar measure created at MD Anderson
Cancer Center (Edwards et al, 2001b; Riley et al, 2002). The local
Symptom Inventory consisted of a series of visual analog scales,
identical to those on the nationwide Symptom Inventory, assessing
the presence and severity of 13 symptoms (pain in treatment site,
other pain, nausea, vomiting, feeling distressed or upset, shortness
of breath, difficulty remembering things, lack of appetite,
diarrhoea, urination change, skin problems in treatment site,
disturbed sleep, and fatigue). This study focused on the presence
and severity of skin problems and pain in treatment site in relation
to total radiation exposure and race.
This report analysed 308 cancer patients who participated in a
local Symptom Inventory conducted at the James P Wilmot Cancer
Center (JPWCC). Similar to the nationwide Symptom Inventory,
completion of the local Symptom Inventory was voluntary and
took approximately 5min. The cancer patients completed the
questionnaire before and after receiving radiation therapy. The
completed Symptom Inventories became part of the patient’s
clinical chart and the forms could be reviewed by clinical staff
during regularly scheduled patient follow-up visits. All patients
included in this study signed a patient authorisation form allowing
the information obtained from the Symptom Inventory to be
stored in a Symptom Inventory database that is maintained by the
James P Wilmot Cancer Center Behavioral Medicine Unit for
research purposes. Permission to maintain the database and for
patient chart review has been obtained from the University of
Rochester Research Subjects Review Board in accordance with
HIPAA policies.
Statistical analyses
The Statistical Package for Social Sciences (SPSS 12.0) was used for
all data processing. Trends and distributions were examined using
histograms and scatterplots. Descriptive statistics were performed
using non-parametric tests (Kruskal Wallis and Mann–Whitney),
median test, independent t-tests, bivariate correlation (Pearson),
and linear regression analyses. Correlative analyses were per-
formed using Pearson’s correlation. Sigma Plot 9.0 was used for
graphical design.
RESULTS
All of the patients in both subsets had normal skin before cancer
treatment (severityp2) and reported their race as ‘White’ or
‘Black’ on the nationwide Symptom Inventory (n¼656) and the
local Symptom Inventory (n¼308). The demographics of the
cancer patients who completed the nationwide and local Symptom
Inventory can be seen in Table 1. The patients were equally
distributed in age groups o61 years of age and X61 years of age
for both questionnaires. The majority of the patients who
completed the nationwide Symptom Inventory were female
(65%) and reported their race as ‘White’ (95%). The nationwide
survey included patients diagnosed with the following types of
cancer: haematologic, head and neck, lung, gastrointestinal,
genitourinary, gynaecologic, breast, or unknown primary (Table 2).
The majority of patients were diagnosed with breast (51.5%),
genitourinary (19.2%), lung (6.8%), or haematologic (6.3%)
cancers. For the local Symptom Inventory, the proportion of
female patients (54%) was similar to the proportion of male
patients (46%), and the majority of the patients reported their race
as ‘White’ (97%). The local survey included patients diagnosed
with the following types of cancer: haematologic, brain and
peripheral nervous system (PNS), head and neck, lung, gastro-
intestinal, genitourinary, gynaecologic, breast, skin, melanoma,
soft tissue sarcoma, bone/cartilage, or unknown primary (Table 2).
The majority of patients were diagnosed with breast (36.7%),
genitourinary (19.2%), brain and PNS (12.7%), or lung (10.4%)
cancers.
Of the 656 cancer patients who completed the nationwide
questionnaire, 245 (37%) patients reported no post-treatment skin
reaction (severity¼0) and 411 (63%) patients reported a post-
treatment skin reaction (severityX1). Of the 308 cancer patients
who completed the local questionnaire, 142 (46%) patients
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sreported no post-treatment skin reaction (severity¼0), and 166
(54%) patients reported a post-treatment skin reaction (sever-
ityX1). In both patient groups, more post-treatment skin reactions
were reported by patients diagnosed with breast or lung cancer
who were in the younger age group (o61 years), female, and
White (Tables 1 and 2).
Reported severity of skin reactions did not differ between
cancer treatments
Out of the 411 cancer patients who reported post-treatment skin
reactions (severityX1) in the nationwide Symptom Inventory, 156
(38%) received chemotherapy, 138 (34%) received radiation
therapy, and 117 (28%) received both chemotherapy and radiation
therapy. Histograms of the severity of skin reactions showed that
the trends for patients receiving either chemotherapy or radiation
therapy skewed to the right, demonstrating that more patients
reported mild skin reactions than severe reactions. Interestingly,
there was a more symmetric distribution of reported skin reactions
in patients receiving both chemotherapy and radiation therapy.
Overall, the mean severity (4.17, 4.2, and 4.6, respectively) for skin
problems in each treatment group showed minimal variation
(Figure 1). A non-parametric Kruskal Wallis test (P¼0.586) and
median test (P¼0.2) did not show any significant difference in the
skin problems by treatment group. Since the histograms portrayed
a different distribution of skin reactions reported by patients
receiving both types of treatment compared to patients receiving
only chemotherapy or only radiation therapy, descriptive statistics
and independent t-test analyses were performed to determine if
there was a difference in the number of moderate (severity¼3–6)
or severe skin (severityX7) skin problems reported by each
treatment group. No variation was found in the proportion of
moderate skin reactions (chemotherapy¼44%, radiation
therapy¼43%, both¼42%) or in severe skin reactions
(chemotherapy¼21%, radiation therapy¼25%, both¼27%).
Patients receiving both chemotherapy and radiation therapy did
not report more severe skin reactions than patients receiving only
radiation therapy (P¼0.657) or chemotherapy (P¼0.314).
Pretreatment expectations did not influence patient report
of post-treatment skin reaction
The nationwide Symptom Inventory included a ‘pretreatment
expectation section’ in which the patient was asked to indicate
which of the 12 symptoms they expected to have as a result of
cancer treatment. The patients were asked to rate their certainty of
side effect occurrence on a five-point horizontal scale anchored by
1¼‘I am certain I will NOT have this’ to 5¼‘I am certain I WILL
have this.’ Of the 407 patients who completed this section of the
nationwide Symptom Inventory, 155 (38%) received chemo-
therapy, 135 (33%) received radiation therapy, and 117 (29%)
received both chemotherapy and radiation therapy. One-way
between-group ANOVA, with Bonferroni correction, showed sig-
nificantly more patients receiving radiation therapy had stronger
expectations (X3) of post-treatment skin problems (62%) than
patients receiving chemotherapy (40%, P¼0.001) or both treatments
(45%, P¼0.003) (Figure 2). However, pretreatment expectations
did not correlate with the reported skin problems post-treatment for
white (r¼0.014, P¼0.781) or black patients (r¼0.021, P¼0.936).
Furthermore, a two-tailed independent t-test showed no significant
difference in pretreatment expectations of post-treatment skin
problems between black and white patients (P¼0.32).
Diagnosis did not significantly correlate with
post-treatment skin reactions in black or white patients
in the nationwide and local Symptom Inventories
The nationwide and local Symptom Inventories involved patients
with various types of cancer. Therefore, it was necessary to
determine whether or not diagnosis influenced the report and
severity of post-treatment skin reactions. Figure 3 shows the mean
severity of reported post-treatment skin reactions for each
diagnosis on the nationwide and local Symptom Inventories. The
majority of white patients (N¼393) in the nationwide Symptom
Inventory who reported a post-treatment skin reaction were
diagnosed with breast (59.8%), lung (10.4%), or genitourinary
(9.4%) cancers. The majority of black patients (N¼18) in the
nationwide Symptom Inventory who reported a post-treatment
skin reaction were diagnosed with breast (50%), genitourinary
(16.7%), or haematologic (16.7%) cancers. The mean skin reaction
severity reported for lung and genitourinary cancers was higher in
white (4.46 and 3.68) than black patients (1.00 and 1.00). In
contrast, the mean skin reaction severity reported for breast, head
and neck, and gynaecologic cancers was higher in black (7.11, 8.00,
and 10.00) than white patients (4.26, 6.33, and 4.37). Bivariate
correlation analysis of the nationwide Symptom Inventory did not
reveal significant relationships between self-reported skin reac-
tions and diagnosis for white (r¼ 0.38, P¼0.456) or black
patients (r¼0.314, P¼0.205). Additionally, linear regression
analysis revealed that diagnosis did not strongly contribute to
post-treatment skin reaction reported by white (SB¼ 0.038,
t¼ 0.747, P¼0.456) or black patients (SB¼0.314, t¼1.323,
P¼0.205).
The distribution of diagnoses in the local Symptom Inventory
differed from the nationwide Symptom Inventory. The majority of
white patients (N¼166) in the local Symptom Inventory who
reported a post-treatment skin reaction were diagnosed with breast
(49%), lung (12.4%), and brain and PNS (11.8%) cancers. In
contrast, black patients (N¼5) in the local Symptom Inventory
who reported a post-treatment skin reaction were diagnosed with
head and neck (60%) or breast (40%) cancer. The mean skin
reaction severity reported for head and neck and breast cancers
was higher in black (6.33 and 5.00) than white patients (3.73 and
2.77). Similar to the nationwide Symptom Inventory, self-reported
Table 1 Demographics for cancer patients
Nationwide Symptom
Inventory (n¼656)
Local Symptom
Inventory (n¼308)
Overall patient demographics/
Age (years)
o61 320 (49%) 159 (52%)
X61 336 (51%) 149 (48%)
Sex
Female 429 (65%) 167 (54%)
Male 227 (35%) 141 (46%)
Race
White 623 (95%) 298 (97%)
Black 33 (5%) 10 (3%)
Nationwide Symptom
Inventory (n¼411)
Local Symptom
Inventory (n¼166)
Demographics for patients reporting post-treatment skin reactions
Age (years)
o61 220 (54%) 111 (67%)
X61 191 (46%) 55 (33%)
Sex
Female 299 (73%) 113 (68%)
Male 112 (27%) 53 (32%)
Race
White 393 (96%) 161 (97%)
Black 18 (4%) 5 (3%)
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sskin reactions did not significantly correlate with diagnosis in
black (r¼ 0.506, P¼0.326) or white patients (r¼ 0.28,
P¼0.726). Furthermore, linear regression analysis confirmed that
the diagnosis did not contribute to the report of post-treatment
skin reactions in black (SB¼ 0.56, t¼ 1.171, P¼0.326) or white
patients (SB¼ 0.28, t¼ 0.351, P¼0.726). Overall, black patients
were more apt to report more severe post-treatment skin problems
than white patients, regardless of diagnosis.
Black patients reported more severe skin problems in
nationwide and local Symptom Inventory
To determine if dark skin pigmentation was protective against
cancer treatment-related skin problems, comparative analysis was
made between the severity of skin reactions reported by white
(n¼393) and black patients (n¼18) in the nationwide sample.
Table 2 Cancer diagnoses for patients in nationwide and local Symptom Inventory
White Black
Type of
cancer All patients
Patients reporting post-
treatment skin reaction All patients
Patients reporting post-
treatment skin reaction
Nationwide Symptom Inventory
Haematologic 37 24 4 3
Head and neck 8 6 1 1
Lung 62 41 1 1
Gastrointestinal 44 31 0 0
Genitourinary 117 37 9 3
Gynaecologic 32 19 2 1
Breast 322 235 16 9
Unknown
primary
10 00
Total 623 393 33 18
Local Symptom Inventory
Haematologic 7 3 0 0
Brain and PNS 37 19 2 0
Head and neck 15 11 4 3
Lung 32 20 0 0
Gastrointestinal 17 6 1 0
Genitourinary 59 10 0 0
Gynaecologic 1 1 0 0
Breast 110 79 3 2
Skin 3 2 0 0
Melanoma 2 1 0 0
Soft tissue
Sarcoma
12 7 0 0
Bone or
cartilage
21 00
Unknown
primary
11 00
Total 298 161 10 5
PNS¼peripheral nervous system.
Mean skin severity
0123456 1 0
Respondent group
Chemotherapy
Radiation
Chemotherapy and
radiation
Figure 1 The severity of skin reactions reported by cancer patients is
not influenced by treatment type. The mean and standard deviations (s.d.’s)
of reported skin problems had minimal variation across treatment groups:
chemotherapy (mean¼4.17, s.d.¼2.7); radiation (mean¼4.2, s.d.¼2.8);
chemotherapy and radiation (mean¼4.6, s.d.¼2.9). No statistically
significant difference was observed (P¼0.586).
Proportion of respondents expecting
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
Respondent group
Chemotherapy
Radiation
Chemotherapy and
radiation
Figure 2 Cancer patients receiving radiation had the strongest
expectations of post-treatment skin problems. A greater proportion of
radiation patients (62%) reported moderate to strong certainty (scaleX3)
of having post-treatment skin problems compared to patients receiving
chemotherapy (40%) or both treatments (45%). These differences were
statistically significant (radiation vs chemotherapy, P¼0.001; radiation vs
both, P¼0.003) by one-way between-groups ANOVA with Bonferroni
correction.
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sDespite a greater increase in mean skin problem score (5.5 vs 4.2)
and standard deviation (3.45 vs 2.7) in black compared to white
patients, the non-parametric Mann–Whitney test showed no
significant difference in the overall reporting of skin problems
(P¼0.152). Histograms portrayed the distribution of skin
problems for white patients as skewed to the right, whereas for
black patients it was U-shaped, suggesting that black patients tend
to report skin reactions at both extremes (i.e., mild or severe). In
concordance with this finding, independent t-test analysis showed
a statistically significant difference (P¼0.001) in the proportion of
white and black patients who reported severe skin reactions
(severityX7). Interestingly, severe skin problems (severityX7)
were reported by 56% of black patients, but only 23% of white
patients (Figure 4).
In order to determine the consistency of the associations defined
by the nationwide Symptom Inventory, statistical analysis was
performed on the severity of skin reactions reported by white
(n¼161) and black patients (n¼5) in the local weekly Symptom
Inventory. Independent t-test analysis showed a statistically
significant difference (P¼0.006) between mean skin problem
score reported by white (mean¼2.98) and black patients
(mean¼5.8). A higher proportion of black patients reported both
moderate (80%) and severe (20%) skin problems than white
patients (39 and 8%, respectively) (Figure 5).
Direct correlation between severity of skin problems and
pain at treatment site
On the local Symptom Inventory questionnaire, the cancer patients
were asked to rate their skin problems and pain at the site of
treatment, as opposed to rating any generalised skin problems or
pain, which was asked in the nationwide Symptom Inventory.
Overall, the severity of skin problems at treatment site reported
after 5 weeks of radiation therapy directly correlated with the
severity of pain at the treatment site by Pearson’s correlation
(r¼0.541, Po0.001). However, when correlative analysis was
performed based on race, the severity of pain at treatment site did
not significantly correlate with severity of skin problems at
treatment site in black patients (r¼ 0.645, P¼0.355). Regression
analysis using one-way ANOVA showed that the report of pain at
treatment site is a potential predictor of the report of skin
problems at treatment site in white (SB¼0.513, t¼7.533,
Po0.001), but not black patients (SB¼ 0.369, t¼ 0.687,
P¼0.541). Additionally, we examined the influence of total
radiation exposure (total Gy) on the report of skin problems at
the treatment site. No correlation was observed between total
radiation dose and reported skin problems at treatment sites by
white (r¼ 0.043, P¼0.602) or black patients (r¼ 0.089,
P¼0.911). Regression analysis by one-way ANOVA confirmed
that total radiation dose is not a potential predictor of reported
skin problems at the treatment site for white (SB¼ 0.043,
t¼ 0.523, P¼0.602) or black patients (SB¼ 0.089, t¼0.126,
P¼0.911).
Nationwide symptom inventory diagnoses
Local symptom inventory diagnoses
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Figure 3 Mean skin severity by cancer diagnoses for patients in the
nationwide and local Symptom Inventories. In the nationwide Symptom
Inventory, the highest mean skin scores were observed for head and neck,
haematologic, gynaecologic, and breast cancers for both black and white
patients. For these four diagnoses, the mean skin severity was higher for
black than white patients, except for haematologic cancers. In the local
Symptom Inventory, the mean skin severity was higher for black than white
patients for breast and head and neck cancers. Overall diagnosis did not
significantly contribute to the report of post-treatment skin reactions by
black or white patients.
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Figure 4 Black patients report more severe post-treatment skin
reactions than white patients in nationwide Symptom Inventory. A total
of 393 white and 18 black patients completed the nationwide Symptom
Inventory. White (43%) patients reported more moderate skin problems
(scale¼3–6) than black (17%) patients. However, black (56%) patients
reported more severe skin problems (scaleX7) than white (23%) patients.
The difference between black and white patients in the reporting of sever
skin problems was statistically significant (P¼0.001).
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sDISCUSSION
Radiation therapy and chemotherapy, separately or combined,
are used worldwide to treat various types of cancer. Despite
advances in medical technology, cancer patients experience
various treatment-related ailments. For many years, it has
been known that UV radiation from sun exposure is a major
cause of skin cancer (Eide and Weinstock, 2005). Radiation
therapy, which uses ionising radiation, and chemotherapy
use toxic agents that damage tissues and DNA (Eide and
Weinstock, 2005; Lopez et al, 2005), often resulting in
nausea, depression, fatigue, and impaired cognitive functioning
(Hickok et al, 2005; Knobf and Sun, 2005). It was not surprising
that cancer patients undergoing radiation therapy expect
and experience skin reactions because treatment is administered
through the skin. Skin problems are one of the most frequently
reported side effects of cancer treatment. This comparative study
provided insight into how skin pigmentation and pretreatment
expectations influence post-treatment skin reactions reported by
cancer patients.
Adverse skin reactions are commonly observed with various
types of cancer treatment (Alley et al, 2002). Common dermato-
logic manifestations from chemotherapy include alopecia, hyper-
pigmentation, hypopigmentation, erythema, and atrophy (Alley
et al, 2002). Radiation-induced skin reactions range from mild
erythema to moist desquamation and necrosis. Additionally, some
chemotherapeutic drugs sensitise the skin to radiation (Alley et al,
2002). Our results showed no difference in the severity of skin
reactions by treatment type (radiation therapy, chemotherapy, or
both). However, black and white patients, regardless of the
pretreatment expectations or diagnosis, differ in their perceptions
of skin reactions and pain induced by cancer treatment. Although
psychological factors are thought to play a role in disease burden
and treatment response (Morse et al, 2003; Olver et al, 2005), our
study did not demonstrate any relationship between pretreatment
expectations and the report of post-treatment skin problems.
Cancer patients receiving only radiation therapy expected more
skin problems than cancer patients receiving chemotherapy or
combination therapy.
Radiation-induced skin reactions are often unpredictable and
vary by individual (Johansson et al, 2002; Lopez et al, 2005).
Melanin, found in human skin, is considered to be protective
against UV and ionising radiation (Nielsen et al, 2006). Darkly
pigmented skin contains more melanin than lightly pigmented
skin. Melanin is an excellent absorber of UV radiation, and its
concentration in the skin is strongly affected by UV radiation
(Nielsen et al, 2006). Untanned skin predominantly contains
melanin in the basal layer of the epidermis, whereas tanned skin
contains melanin throughout the epidermis. Melanin acts to
remove free radicals and reactive oxygen species that are generated
in skin by UV radiation (Hoogduijn et al, 2004). Melanocytes, the
cells that synthesise melanin, are more susceptible to the damaging
effects of oxidative stress than other cell types in the skin, such as
keratinocytes and fibroblasts (Hoogduijn et al, 2004). Repeated
exposure to UV or ionising radiation can disrupt melanin
production and result in irreversible skin damage. Even though
melanin can protect melanocytes and keratinocytes from oxidative
DNA damage, in vitro experiments have demonstrated that the
presence of reactive oxygen species during melanin synthesis can
increase DNA damage (Hoogduijn et al, 2004). Therefore, darkly
pigmented skin may be more susceptible to DNA damage from
radiation due to the higher rate of melanin synthesis compared to
lightly pigmented skin. Likewise, severe ionising radiation-induced
skin reactions are often observed in sun-exposed regions of the
skin (Harper et al, 2004). Besides skin pigmentation, radiation-
induced skin injury is also influenced by treatment area on the
body (Stone et al, 2003). The head and neck region, as well as the
thorax region, are more prone to skin damage from radiation than
the pelvic region of the body (Stone et al, 2003). In this study, the
black patients who reported post-treatment skin reactions were
diagnosed with head and neck cancer (60%) and breast cancer
(40%). Although diagnosis did not significantly correlate with the
report of post-treatment skin reactions for white or black patients,
the statistically significant difference in mean severity of skin
reaction between the two racial backgrounds could be due to the
dissimilar distribution of diagnoses. Future studies involving a
larger population of black cancer patients would clarify these
findings.
In this study, black patients reported more severe post-
treatment skin reactions than white patients. Furthermore,
the total radiation exposure directly correlated with the severity
of skin reactions reported by black patients, but not by
white patients. Therefore, the high melanin content of
darkly pigmented skin did not appear protective. It is possible
that skin reactions are not visualised in darkly pigmented
skin until damage is more severe. For example, pinching of skin
leaves a more easily visible red mark on fair-skinned individuals,
because pigment interferes with the visualisation of redness in
dark-skinned individuals. Additionally, radiation-induced distur-
bance of skin pigmentation would be more noticeable in more
darkly pigmented skin.
Over the past few years, the influence of race (ancestry and
physical characteristics) and ethnicity (behavioural and cultural
distinctions) on the experience of pain has become a growing area
of research (Edwards et al, 2001a; Morse et al, 2003). Many studies
have demonstrated that black patients report higher levels of
clinical pain and greater pain-related disability than white patients
(Edwards et al, 2001a; Campbell et al, 2005). Additionally, racial
differences in pain have been found to vary by anatomical site. For
instance, black patients tend to report more pain associated with
glaucoma, arthritis, orofacial injury, and migraine headaches
(Riley et al, 2002; Campbell et al, 2005). Riley et al (2002) and
Sanders et al (1992) showed that given the same pain stimulus,
black patients had a stronger perception and response to the pain
stimulus than white patients. Our study supported these previous
findings by showing a direct correlation between the severity of
self-reported pain and skin reaction at the treatment site in black
patients, but not in white patients.
The therapeutic effects of ionising radiation are based on the
greater capacity of normal tissues to repair DNA damage
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Figure 5 Black patients reported more post-treatment skin reactions
than white patients in local Symptom Inventory. A total of 156 white and 8
black patients completed the local Symptom Inventory. Black patients
reported more moderate (80%) and severe (20%) skin reactions compared
to white patients (39 and 8%, respectively). Despite the small sample size,
these data support the results from the nationwide Symptom Inventory.
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radiation treatment for cancer must be administered through
the skin, (Harper et al, 2004). Even though skin is not the
target of treatment, it is damaged during the treatment process.
Radiation-induced skin injury is influenced by treatment-related
factors, such as volume of treatment area and fraction dose
size, and by patient-related factors (Harper et al, 2004). For
instance, more severe radiation-induced skin problems occur in
large-breasted women and obese individuals. Other patient-related
risk factors for skin problems from cancer treatment include
age, smoking status, infection of surgical wounds, and genetics
(Harper et al, 2004). Mutations in the ataxia-telangiectasia (ATM)
gene have been associated with increased radiosensitivity
and radiation-induced morbidity (Iannuzzi et al, 2002;
Harper et al, 2004). ATM heterozygosity occurs in approximately
1% of the general population and predicts subcutaneous late
responses to radiation therapy, but not acute effects (Iannuzzi
et al, 2002). Therefore, patients containing a mutated ATM gene
might be predisposed to late radiation-induced skin injury.
It is also known that point mutations and deletions in
mitochondrial DNA (mtDNA) increase cellular radiosensitivity
(Prithivirajsingh et al, 2004). Unlike nuclear DNA, mtDNA
lacks an efficient DNA repair mechanism and is more vulnerable
to the accumulation of DNA damage (Prithivirajsingh et al, 2004;
Wilding et al, 2006). High levels of mtDNA mutations in the skin
could predispose cancer patients to radiation-induced skin
problems. Unfortunately, we were unable to correlate the Symptom
Inventory data with genetic alterations because the collection of
blood and tissue samples from patients was not performed in this
observational study based on clinical data. Next steps in under-
standing the differences observed in this study would include
assessing the relationship of our findings to these known
contributors to radiation sensitivity. These explanations for the
difference in the severity of post-treatment skin reactions reported
by black and white patients should be explored in a future clinical
study.
Although this comparative study was able to demonstrate
statistically significant racial differences in the severity of
post-treatment skin reactions and pain reported by cancer
patients, black subjects were underrepresented in both surveys
in comparison to white subjects. The small sample size of
black patients could have biased the statistical results, especially
if these individuals represent extremes of the general population.
Further clinical studies should include a larger sample population
of black patients to determine more precisely the distribution
of reported post-treatment skin reactions and pain in black
and white patients. Additionally, a larger sample size would
increase the statistical power and validity of the results, as well as
the ability to understand specific consequences of treatments
such as anti-epidermal growth factor receptor therapy,
which commonly cause an acne-like rash (Sipples, 2006).
Additionally, future studies would benefit from extensive clinical
data, such as disease stage, area of treatment, documentation
of skin problems, and blood samples to examine predisposing
genetic factors. Our study did show similar trends in two separate
surveys (national and local); both suggesting that black and
white patients differ in their perception of skin reactions and
pain induced by cancer treatment. Further elucidation of the
role of skin pigmentation and the influence of race and ethnicity
on skin reactions and pain experienced by cancer patients could
improve cancer treatment symptom management for future
patients.
ACKNOWLEDGEMENTS
This work was supported by NCI Grants 1R25-CA102618-01A1 and
U10-CA37420.
REFERENCES
Alley E, Green R, Schuchter L (2002) Cutaneous toxicities of cancer therapy.
Curr Opin Oncol 14: 212–216
Campbell CM, Edwards RR, Fillingim RB (2005) Ethnic differences in
responses to multiple experimental pain stimuli. Pain 113: 20–26
Edwards CL, Fillingim RB, Keefe F (2001a) Race, ethnicity and pain. Pain
94: 133–137
Edwards RR, Doleys DM, Fillingim RB, Lowery D (2001b) Ethnic
differences in pain tolerance: clinical implications in a chronic pain
population. Psychosom Med 63: 316–323
Eide MJ, Weinstock MA (2005) Association of UV index, latitude, and
melanoma incidence in nonwhite populations – US Surveillance,
Epidemiology, and End Results (SEER) Program, 1992 to 2001. Arch
Dermatol 141: 477–481
Freak J (2004) Understanding symptoms and management of skin
disorders. Nurs Times 100: 34–37
Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ
(2005) Prevalence and treatment of psoriasis in the United Kingdom: a
population-based study. Arch Dermatol 141: 1537–1541
Harper JL, Franklin LE, Jenrette JM, Aguero EG (2004) Skin toxicity during
breast irradiation: pathophysiology and management. South Med J 97:
989–993
Hickok JT, Morrow GR, Roscoe JA, Mustian K, Okunieff P (2005)
Occurrence, severity, and longitudinal course of twelve common
symptoms in 1129 consecutive patients during radiotherapy for cancer.
J Pain Symptom Manage 30: 433–442
Hoogduijn MJ, Cemeli E, Ross K, Anderson D, Thody AJ, Wood JM (2004)
Melanin protects melanocytes and keratinocytes against H2O2-induced
DNA strand breaks through its ability to bind Ca
2+. Exp Cell Res 294:
60–67
Iannuzzi CM, Atencio DP, Green S, Stock RG, Rosenstein BS (2002)
ATM mutations in female breast cancer patients predict for an increase
in radiation-induced late effects. Int J Radiat Oncol Biol Phys 52:
606–613
Johansson S, Svensson H, Denekamp J (2002) Dose response
and latency for radiation-induced fibrosis, edema, and neuropathy
in breast cancer patients. Int J Radiat Oncol Biol Phys 52: 1207–
1219
Knobf MT, Sun Y (2005) A longitudinal study of symptoms and self-care
activities in women treated with primary radiotherapy for breast cancer.
Cancer Nurs 28: 210–218
Koo J, Lebwohl A (2001) Psycho dermatology: the mind and skin
connection. Am Fam Physician 64: 1873–1878
Lopez E, Guerrero R, Nunez MI, del Moral R, Villalobos M,
Martinez-Galan J, Valenzuela MT, Munoz-Gamez JA, Oliver FJ,
Martin-Oliva D, Ruiz de Almodovar JM (2005) Early and late skin
reactions to radiotherapy for breast cancer and their correlation with
radiation-induced DNA damage in lymphocytes. Breast Cancer Res 7:
R690–R698
Morse R, Rodgers J, Verrill M, Kendell K (2003) Neuropsychological
functioning following systemic treatment in women treated for breast
cancer: a review. Eur J Cancer 39: 2288–2297
Nielsen KP, Zhao L, Stamnes JJ, Stamnes K, Moan J (2006) The importance
of the depth distribution of melanin in skin for DNA protection
and other photobiological processes. J Photochem Photobiol B 82:
194–198
Olver IN, Taylor AE, Whitford HS (2005) Relationships between patients’
pre-treatment expectations of toxicities and post chemotherapy experi-
ences. Psychooncology 14: 25–33
Prithivirajsingh S, Story MD, Bergh SA, Geara FB, Ang KK, Ismail SM,
Stevens CW, Buchholz TA, Brock WA (2004) Accumulation of the
common mitochondrial DNA deletion induced by ionizing radiation.
FEBS Lett 571: 227–232
Skin reactions reported by cancer patients differ by race
JL Ryan et al
20
British Journal of Cancer (2007) 97(1), 14–21 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sRiley III JL, Wade JB, Myers CD, Sheffield D, Papas RK, Price DD (2002)
Racial/ethnic differences in the experience of chronic pain. Pain 100:
291–298
Sanders SH, Brena SF, Spier CJ, Beltrutti D, McConnell H, Quintero O
(1992) Chronic low back pain patients around the world: cross-cultural
similarities and differences. Clin J Pain 8: 317–323
Schreier AM, Williams SA (2004) Anxiety and quality of life of women who
receive radiation or chemotherapy for breast cancer. Oncol Nurs Forum
31: 127–130
Sipples R (2006) Common side effects of anti-EGFR therapy: acneform
rash. Semin Oncol Nurs 22: 28–34
Stone HB, Coleman CN, Anscher MS, McBride WH (2003) Effects of
radiation on normal tissue: consequences and mechanisms. Lancet Oncol
4: 529–536
Wilding CS, Cadwell K, Tawn EJ, Relton CL, Taylor GA, Chinnery PF,
Turnbull DM (2006) Mitochondrial DNA mutations in
individuals occupationally exposed to ionizing radiation. Radiat Res
165: 202–207
Skin reactions reported by cancer patients differ by race
JL Ryan et al
21
British Journal of Cancer (2007) 97(1), 14–21 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s